Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 10

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 10
---
 analyze changes in ribonucleic acid (RNA) to assess risk signals associated with infectious diseases and certain cancers. Our screening workflow includes sample processing, RNA extraction, hybridization to microarray (GeneChip™) platforms, and proprietary algorithmic analysis to generate a report delivered to the referring healthcare provider. We currently offer assays that screen for multiple cancer types and inflammatory conditions, among others. We derive revenue by processing samples referred by third-party healthcare providers and collection centers in Malaysia. We are focused on quality, turnaround time, and ongoing improvements to analytical software and processes.

Specialty Chemicals (Chemrex)

Chemrex (acquired December 31, 2020) distributes chemical raw materials—principally fiber-reinforced polymer (FRP) inputs—to manufacturers in Malaysia and broader Southeast Asia across medical, appliance, aerospace, automotive, mechanical, and electronics end-markets. Chemrex purchases a range of resins and related materials from domestic and international suppliers and sells to established customers, while maintaining quality control practices (including manufacturer certificates of analysis and inventory controls). Chemrex has initiated a multi-phase transition toward a contract development and manufacturing organization (“CDMO”) model with facility upgrades, equipment procurement, and quality system enhancements aimed at achieving applicable good manufacturing practice (GMP) standards over time.

Strategy

Our strategy is to (i) expand adoption of our RNA-based screening services through partnerships with healthcare providers and labs, (ii) stabilize and grow Chemrex’s distribution activities while progressing its CDMO build-out to target higher-margin opportunities, and (iii) pursue selective partnerships and corporate development initiatives that complement our core capabilities. The Company is also evaluating digital health initiatives and treasury strategies designed to support liquidity and capital markets readiness; as of June 30, 2025, we did not hold digital assets while management continued to assess proposals and allocation approaches.

| 5 |

Recent Developments

| · 
 · | Ethereum Treasury Strategy. On March 5, 2025, our Board approved an Ethereum-focused corporate treasury strategy. On March 7, 2025, the company announced that it entered into a strategic partnership with ML Tech to support implementation of Ethereum-based growth and treasury initiatives. The Company did not hold digital assets as of June 30, 2025, and management continues to evaluate timing and structure of any deployment under this strategy.                                                                    
 Nasdaq Compliance and Reverse Split. Following a previously disclosed bid-price deficiency process, we effected a 1-for-10 reverse stock split on April 7, 2025